We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Sponsor content
356 result(s) found, displaying 1 to 10
-
Apr-2026Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Apr-2026Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Apr-2026Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Apr-2026Prescription medicine evaluationActive ingredient: belzutifan.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ENFLONSIA clesrovimab 105 mg in 0.7 mL solution for injection prefilled syringe.
-
Prescription medicine decision summaryEnflonsia has been approved to help prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Prescription medicine registrationActive ingredients: sotatercept.
-
Prescription medicine registrationActive ingredients: clesrovimab.
-
Prescription medicine registrationActive ingredients: pembrolizumab.